WELLBUTRIN
Pronunciation: byoo-PROE-pee-on (WEL-byoo-trin)


What it isNorepinephrine-dopamine reuptake inhibitor; depression. Smoking cessation is the SR product ZYBAN, and SAD prevention is WELLBUTRIN XL.
Why this oneFar less sexual dysfunction and weight gain than SSRIs; hence use as an addition or substitute.
What limits itLowers the seizure threshold, so avoid in eating disorders and with alcohol withdrawal. A strong CYP2D6 inhibitor.
Animated chart of estimated U.S. prescriptions per year, Antidepressants (1957–2026). Bupropion enters in 1989 (estimated).
Legacy pregnancy categoryC
Defining liabilityDose-related seizures and delayed cardiotoxicity are prominent in overdose, especially with extended-release products.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Major depressive disorder | Adults | 100 mg BID | 100 mg TID (300 mg/day) | 450 mg/day (≤150 mg per dose) |
Titration After 3 days may increase to 300 mg/day; increases ≤100 mg/day per 3-day period
Renal GFR <90 mL/min: consider reduced dose and/or frequency
Hepatic Moderate–severe (Child-Pugh 7–15): max 75 mg/day; mild (Child-Pugh 5–6): consider reduced dose and/or frequency
Not approved for smoking cessation; pediatric safety and effectiveness not established.
Available strengths
Pregnancy First-trimester epidemiologic data show no increased overall malformation risk; weigh risks of untreated depression.
Lactation Bupropion and metabolites present in milk (~2% of maternal weight-adjusted dose); seizures reported in breastfed infants (relationship unclear).
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 75 mg | tab | 30 qd | $2.78 | offered |
| 100 mg | tab | 30 qd | $3.39 | offered |
Other forms: Bupropion hydrobromide ER (APLENZIN) · Bupropion SR (WELLBUTRIN SR) · Bupropion XL (WELLBUTRIN XL) · Bupropion XL 450 mg (FORFIVO XL)
Available combined with: dextromethorphan / bupropion · naltrexone / bupropion
Generic entry1999
This drug is routinely called serotonergic. By Gillman’s human-effect criteria it does not raise serotonin in the synapse.
No clinically significant SRI activity.
Label contraindicationMAOIs (psychiatric) concurrently or within 14 days; starting in patients on linezolid or IV methylene blue — hypertensive reactions. The label governs prescribing; Gillman’s point concerns serotonin toxicity only.
Gillman’s four human testsA measurable SERT affinity that fails all four is not clinical serotonicity.
Non-elevating actionNone recorded
Evidence confidenceHigh
Background: what serotonicity is · what is and is not an SRI · what counts as a relevant MAOI.
Open Bupropion in the interactive console ↗
Open Bupropion in the interactive console ↗